Predictive Oncology (NASDAQ: POAI), a knowledge-driven
company focused on applying artificial intelligence (“AI”) to personalized
medicine and drug discovery, recently reported that its Helomics subsidiary is
making headway toward its goal of developing an AI-driven predictive model of ovarian
cancer (http://ibn.fm/mENY6).
An article discussing the company reads, “This achievement will be a key
milestone for the company’s CancerQuest2020 initiative. . . . CancerQuest2020
is focused on building an AI-driven model of ovarian cancer that will predict
drug response and outcome leveraging Helomics’ huge knowledge base of tumor
profiles. Predictive models embody the knowledge from these profiles to create
a ‘computational expert’ or a ‘virtual patient’ that can be queried. Predictive
models such as these are of high value to pharmaceutical companies as they can
be used to quickly select patients for clinical trials and assess potential new
drugs or biomarkers computationally (‘in silico’) before initiating expensive
laboratory experiments. In short, Helomics’ predictive models will save time
and money in the search for new targeted therapies. . . . Using the power of
AI, the model draws on data generated from over 150,000 tumor cases.”
To view the full article, visit http://ibn.fm/t0WsP
About Predictive Oncology Inc.
Predictive Oncology operates through three segments
(domestic, international and other) that contain four subsidiaries; Helomics,
TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial
intelligence to its rich data gathered from patient tumors to both personalize
cancer therapies for patients and drive the development of new targeted
therapies in collaborations with pharmaceutical companies. Helomics’
CLIA-certified lab provides clinical testing that assists oncologists in
individualizing patient treatment decisions, by providing an evidence-based
road map for therapy. In addition to its proprietary precision oncology platform,
Helomics offers boutique CRO services that leverage its TruTumor(TM),
patient-derived tumor models coupled with a wide range of multi-omics assays
(genomics, proteomics and biochemical), and an AI-powered proprietary
bioinformatics platform to provide a tailored solution to its clients’ specific
needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid
approach to growing tumors in the laboratory, which essentially “fools” cancer
cells into thinking they are still growing inside a patient. Its proprietary
Oncology Discovery Technology Platform Kits will assist researchers and
clinicians to identify which cancer cells bind to specific biomarkers. Once the
biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology
Platforms, which isolate and help categorize an individual patient’s
heterogeneous tumor samples to enable the development of patient-specific
treatment options. Helomics and TumorGenesis are focused on ovarian cancer.
Predictive Oncology’s Skyline Medical division markets its patented and
FDA-cleared STREAMWAY System, which automates the collection, measurement and
disposal of waste fluid, including blood, irrigation fluid and others, within a
medical facility, through both domestic and international divisions. The
company has achieved sales in five of the seven continents through both direct
sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
